Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

97

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Tags:

Previous Article

Interplay between mesothelial and immune cells in the tumor microenvironment

LSD analogue with potential for treating schizophrenia

Related Posts

TANGO2 is an acyl-CoA binding protein

TANGO2 is an acyl-CoA binding protein

54

Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype

Targeting microRNA-dependent control of X chromosome in...

57

Photoswitchable allosteric and dualsteric ligands in GPCR pharmacology

Photoswitchable allosteric and dualsteric ligands in GP...

48